GlympaTM

Empagliflozin & Linagliptin
SGLT2 Inhibitor & DPP-4 Inhibitor Combination (Antidiabetic Preparations)

Indication:

Glympa^TM is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Empagliflozin is indicated to reduce the risk of cardiovascular death in adults with type 2 diabetes mellitus and established cardiovascular disease.

Dosage & Administration:

The recommended dose is Glympa^TM 10/ 5 once daily, taken in the morning, with or without food. Dose may be increased to Glympa^TM 25/5 once daily.

Preparation:

Glympa^TM Tablet: Each box contains 20 tablets in Blister pack.
Glympa^TM Tablet: Each box contains 10 tablets in Blister pack.